The first open tour around the Medsintez plant premises was arranged for the Sverdlovsk Region's Ministry of Health and the Ministry of Industry and Science.
During the event, representatives of the Ministry of Health and the Ministry of Industry and Science visited the plant's production shops and research laboratories, got acquainted with manufacturing processes for the main products - infusion solutions, finished forms, substances of genetically engineered human insulin and the Triazavirin antiviral drug as well as chemically synthesised substances.
The Medsintez plant was one of the first in Russia industrial manufacturers of finished dosage forms of genetically engineered human insulin, who met GMP EC requirements.The plant management shared with the ministry representatives further growth prospects, which are mainly related to releasing new types of medical products.The pharmaceutical direction is driven by the implementation of some projects dealing with arranging the manufacturing of medicines and active pharmaceutical substances of genetic-engineered and analog insulins (Aspart and Glargin) for subsequent use in our own production of finished dosage forms.In September 2017, Rosinsulin, an insulin substance, was registered.In late 2018, Rosinsulin Aspart, an analogue insulin substance, was registered.Finished dosage forms based on Aspart, Medsintez's proprietary insulin substance, are planned to enter the market by 2020, while Glargin insulin - by 2021.The implementation of the project will allow to give up purchasing foreign substances and create a full-cycle insulin production.
Also, the plant has launched the production of Triazavirin, an innovative domestic drug offering a wide-range antiviral activity and effective as treatment and prevention of viral diseases, including the influenza virus.The development was awarded the prestigious PrixGalienRussia prize. In 2017, the medication was included into the federal clinical guidelines of the Ministry of Health of the Russian Federation as one of four antiviral drugs for influenza.Triazavirin is currently undergoing additional clinical trials to expand its scope use.Doctors successfully use the drug not only with influenza, but also with acute respiratory viral infections, tick-borne encephalitis, hemorrhagic fevers and other conditions.
The visitors noted the Medsintez plant's commercial scale and innovation potential as well as expressed their confidence in a promising and fruitful cooperation.
During the event, representatives of the Ministry of Health and the Ministry of Industry and Science visited the plant's production shops and research laboratories, got acquainted with manufacturing processes for the main products - infusion solutions, finished forms, substances of genetically engineered human insulin and the Triazavirin antiviral drug as well as chemically synthesised substances.
The Medsintez plant was one of the first in Russia industrial manufacturers of finished dosage forms of genetically engineered human insulin, who met GMP EC requirements.The plant management shared with the ministry representatives further growth prospects, which are mainly related to releasing new types of medical products.The pharmaceutical direction is driven by the implementation of some projects dealing with arranging the manufacturing of medicines and active pharmaceutical substances of genetic-engineered and analog insulins (Aspart and Glargin) for subsequent use in our own production of finished dosage forms.In September 2017, Rosinsulin, an insulin substance, was registered.In late 2018, Rosinsulin Aspart, an analogue insulin substance, was registered.Finished dosage forms based on Aspart, Medsintez's proprietary insulin substance, are planned to enter the market by 2020, while Glargin insulin - by 2021.The implementation of the project will allow to give up purchasing foreign substances and create a full-cycle insulin production.
Also, the plant has launched the production of Triazavirin, an innovative domestic drug offering a wide-range antiviral activity and effective as treatment and prevention of viral diseases, including the influenza virus.The development was awarded the prestigious PrixGalienRussia prize. In 2017, the medication was included into the federal clinical guidelines of the Ministry of Health of the Russian Federation as one of four antiviral drugs for influenza.Triazavirin is currently undergoing additional clinical trials to expand its scope use.Doctors successfully use the drug not only with influenza, but also with acute respiratory viral infections, tick-borne encephalitis, hemorrhagic fevers and other conditions.
The visitors noted the Medsintez plant's commercial scale and innovation potential as well as expressed their confidence in a promising and fruitful cooperation.